 |
|
|
| |
Elbasvir/Grazoprevir + Sofosbuvir ± Ribavirin in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 3
Infection and Compensated Cirrhosis: The C-ISLE Study
|
| |
| |
Reported by Jules Levin
26th Conference of the Asian Pacific Association for the Study of the Liver;
February 15-19, 2017; Shanghai, China
Chaudhri E1; Foster GR2; Agarwal K3; Cramp ME4; Moreea S5;
Barclay S6; Collier J7; Brown AS8; Ryder SD9; Ustianowski A10;
Forton DM11; Fox R12; Gordon F13; Rosenberg WM14; Mutimer DJ15; Du J1; Gilbert CL1; Asante-Appiah E1; Wahl J1; Barr E1; Haber B1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2The Royal London Hospital, London, UK; 3Institute of Liver Studies, Kings College Hospital, London, UK; 4South West Liver Unit, Derriford Hospital and Peninsula School of Medicine and Dentistry, Plymouth, UK; 5Bradford Teaching Hospitals Foundation Trust, Bradford, UK; 6Glasgow Royal Campus, Glasgow, UK; 7John Radcliffe Hospital, Oxford, UK; 8Imperial College Healthcare, London, UK; 9NIHR Biomedical Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK; 10North Manchester General Hospital, Manchester, UK; 11St. Georges University of London, London, UK; 12Gartnavel General Hospital, Glasgow, UK; 13Hepatology Joint Clinical Research Unit, Bristol, UK; 14University College London, London, UK; 15QE Hospital, Birmingham, UK
|
| |
|
|
|
|
|
